Related Experiment Video
Updated: Mar 8, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.2K
Management strategies for atrial fibrillation
Peysh A Patel1, Noman Ali2, Andrew Hogarth1
11 Department of Cardiology, Leeds General Infirmary, Leeds LS1 3EX, UK.
Journal of the Royal Society of Medicine
|January 21, 2017
Summary
Atrial fibrillation (AF) management involves controlling the arrhythmia and preventing strokes. Novel oral anticoagulants show promise for stroke prevention in AF patients, but further research is needed.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is the most common heart arrhythmia, especially in older adults.
- AF increases mortality risk due to complications like stroke.
- Current management focuses on rhythm/rate control and anticoagulation for stroke prevention.
Purpose of the Study:
- To review current management strategies for atrial fibrillation.
- To evaluate the role of novel oral anticoagulants (NOACs) in stroke prevention compared to warfarin.
- To highlight recent controversies and future research directions regarding NOACs.
Main Methods:
- Literature review of atrial fibrillation treatments.
- Analysis of evidence for novel oral anticoagulants versus warfarin.
- Discussion of emerging controversies and research needs.
Main Results:
- Catheter ablation is an alternative treatment for selected AF patients.
- Novel oral anticoagulants demonstrate comparable efficacy to warfarin for stroke prevention.
- NOACs are associated with fewer bleeding complications than warfarin.
Conclusions:
- Novel oral anticoagulants represent a significant advancement in stroke prevention for atrial fibrillation patients.
- Further research is essential to understand NOAC mechanisms and develop antidotes.
- Optimizing NOAC use requires addressing recent controversies and establishing clear treatment guidelines.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
553
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
553
01:26Atherosclerosis III: Management
540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
01:26Mitral Stenosis III: Medical Management
398
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
398
01:29Venous Thrombosis III: Interprofessional Care
432
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432
01:25Aortic Regurgitation III: Medical Management
528
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
528
01:30Heart Failure V: Medical Management
446
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
446